Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (11826)	11/13/2018 2:12:57 PM
From: Miljenko Zuanic	Respond to of 12215

More advance NASH subjects (fat content, NASH/Fibrosis score), on mean fat reduction 400 and 600 mg dose are equal, on NASH resolution/Fibrosis reduction/cirrhosis conversion/liver enzymes...there is dose response. Results are good, but not of 2809/3196 magnitude (on lipids/metabolic). GLMD is the only company that has 600Kg drug API ready...only one that has SERIOUS PLANING for P3! I am bit concerned on 3196 and plan for P3 (1Q-19), do not see drug-product contract manufacturing cost?????